Regeneron will not acquire 23andMe’s telehealth subsidiary, Lemonaid Health, which the company purchased for approximately $400 million in 2021.

CT is your last chance to file a claim with 23andMe for a 2023 data breach that may have compromised your genetic data.

23andMe has found itself a buyer after biotech Regeneron won an auction to buy the bankrupt genetics company for $256m. As part of a court-supervised sale, the auction will see Regeneron acquire ...

Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its bankruptcy filing. The deal excludes 23andMe’s telehealth subsidiary ...

Regeneron will be keeping all of 23andMe’s employees, Jensen added. As part of the court-supervised sale process, 23andMe required all bidders to guarantee that they will comply with its privacy ...

Regeneron, the Tarrytown, New York-based pharmaceutical company, agreed to purchase 23andMe for $256 million, following the saliva test kit company's bankruptcy in March.

Regeneron acquires 23andMe for $256M following bankruptcy auction Regeneron will take over key assets including 23andMe’s Personal Genome Service, Biobank, Total Health, and research operations, ...

Regeneron, a biotech company, will acquire 23andMe for $256 million and vowed to comply with the genetic testing company's privacy policies.

Biotechnology leader Regeneron Pharmaceuticals is acquiring genetic testing firm 23andMe for $256 million following its bankruptcy filing. The deal excludes 23andMe’s telehealth subsidiary ...

Regeneron Pharmaceuticals said it will acquire 23andMe's business. What happened to 23andMe? Should you delete your data? What to know.

Biotechnology company Regeneron Pharmaceuticals is buying 23andMe for $256 million, two months after the genetic testing company filed for Chapter 11 bankruptcy protection.